πŸ† TopRankLand
← All Rankings
Health

Best Continuous Glucose Monitors 2026

Over-the-counter and prescription CGMs ranked by sensor accuracy, wear time, daily cost, app insights and coaching.

Last updated: 2026-10-06 Β· 13 entries tracked daily

Rank Trend β€” Top 10

Lower = better rank. Showing last 37 days.

Current Rankings

#1
Stelo Dexcom
$49.50 / 15-day sensor 9.3/10

The most accurate no-prescription glucose biosensor in 2026, running Dexcom's G7-grade sensor for 15 days at the lowest daily cost of any OTC option.

Sensor Accuracy (MARD) 9.2
Wear Time 9.3
Daily Cost & Value 9.5
App & Insights 8.5
Coaching & Support 7.0
#2
$89+ / 15-day sensor 9.1/10

The accuracy leader at 8.0% MARD, holding that precision across a full 15.5 days of wear with a 12-hour grace period, which cuts sensor changes by a third compared with the 10-day G7.

Sensor Accuracy (MARD) 9.8
Wear Time 9.3
Daily Cost & Value 7.8
App & Insights 9.0
Coaching & Support 8.5
#3
Lingo Abbott
$49 / 14-day sensor 9.0/10

Abbott's OTC biosensor built around a metabolic-coaching app that scores your glucose response to food, sleep and exercise with minute-by-minute data.

Sensor Accuracy (MARD) 9.0
Wear Time 8.8
Daily Cost & Value 8.8
App & Insights 9.2
Coaching & Support 8.0
#4
~$70/mo 8.9/10

A 15-day sensor with an 8.2% MARD and the smallest form factor on the market, delivering hospital-grade accuracy at a low daily cost.

Sensor Accuracy (MARD) 9.3
Wear Time 9.3
Daily Cost & Value 8.2
App & Insights 8.5
Coaching & Support 8.0
#5
G7 Dexcom
$89+ / sensor 8.8/10

The accuracy benchmark at 8.2% MARD with a 30-minute warmup, native Apple Watch support and insulin-pump integration, cleared down to age 2, the CGM I trust most for medical-grade glucose management.

Sensor Accuracy (MARD) 9.6
Wear Time 8.5
Daily Cost & Value 6.5
App & Insights 9.0
Coaching & Support 8.5
#6
Eversense 365 Senseonics
$199–$1,000 / yr 8.6/10

A fully implantable sensor placed under the upper-arm skin that reports glucose for a full year on a single insertion, holding an 8.8% MARD across all 365 days with a removable rechargeable transmitter.

Sensor Accuracy (MARD) 8.9
Wear Time 10.0
Daily Cost & Value 7.6
App & Insights 8.2
Coaching & Support 8.0
#7
Levels Levels Health
$199/yr + sensors 8.5/10

The most polished metabolic-health software, layering food scoring, AI coaching and trend analysis on top of an Abbott or Dexcom sensor.

Sensor Accuracy (MARD) 8.8
Wear Time 8.8
Daily Cost & Value 6.0
App & Insights 9.4
Coaching & Support 8.2
#8
Nutrisense Nutrisense
$179/mo 8.4/10

The strongest human-in-the-loop program, bundling a registered dietitian with every plan for people who want real behavior change with expert guidance.

Sensor Accuracy (MARD) 8.8
Wear Time 8.5
Daily Cost & Value 6.2
App & Insights 8.8
Coaching & Support 9.5
#9
Veri Veri
$109/mo 8.3/10

A $109 a month membership pairing Abbott Libre sensors with the cleanest food-logging app in this category, and a $39 app-only tier if you source sensors elsewhere. I recommend it to people who want glucose data translated straight into meal decisions.

Sensor Accuracy (MARD) 9.0
Wear Time 8.6
Daily Cost & Value 8.2
App & Insights 9.0
Coaching & Support 7.6
#10
Signos Signos
$199-$399/mo 8.2/10

The weight-loss specialist with FDA-cleared weight-management claims, using AI to time meals and workouts around your real glucose curve, with GLP-1 support.

Sensor Accuracy (MARD) 8.6
Wear Time 8.5
Daily Cost & Value 6.0
App & Insights 8.9
Coaching & Support 8.5
#11
M1 Ultrahuman
$299/mo (2 sensors) 8.0/10

The athlete and biohacker platform, pairing real-time glucose with a metabolic-scoring app that ties into sleep, workouts and its Ring Air ecosystem.

Sensor Accuracy (MARD) 8.4
Wear Time 8.2
Daily Cost & Value 6.8
App & Insights 8.8
Coaching & Support 7.5
#12
GS3 SIBIONICS
~$40 / 14-day sensor 7.8/10

The value newcomer, packing 14-day wear, voice food logging and AI meal analysis into a 1.5g sensor at one of the lowest sticker prices around.

Sensor Accuracy (MARD) 8.0
Wear Time 8.2
Daily Cost & Value 8.8
App & Insights 7.8
Coaching & Support 6.5
#13
January AI January AI
$28/mo 7.5/10

The only pick that predicts glucose response without a sensor, scanning meals with generative AI so you can see the impact before you eat.

Sensor Accuracy (MARD) 7.0
Wear Time 7.0
Daily Cost & Value 9.2
App & Insights 8.6
Coaching & Support 7.0

Today's Analysis Β· 2026-10-06

I checked this week for anything that would move the needle and came up with more confirmation than change. Stelo holds first because it still does the one thing most shoppers actually need: a $49.50, 15-day sensor with no prescription and no clinic visit. That price-to-access ratio is why it beats sensors with better raw accuracy. G7 15 Day stays at second on the strength of its 8.0% MARD across a full 15.5 days, the tightest accuracy-to-wear-time combination I have tested in this category. Lingo holds third because its coaching layer, built around a glucose score you check daily, keeps people opening the app after the novelty of a new sensor wears off, which is the real failure point for most OTC CGM users. Libre 3 Plus sits just behind it at fourth with the smallest sensor on the market and an 8.2% MARD, a genuinely tiny trade-off for better comfort. Eversense 365 keeps its middle-of-the-pack spot because an implant that lasts a full year solves wear-time anxiety completely, but the $199 to $1,000 yearly range and the need for a brief in-office insertion keep it out of the top tier for casual buyers. Further down, Signos and Nutrisense earn their ranks mainly on coaching depth, and January AI stays last because skipping the sensor entirely still means guessing instead of measuring. I noticed a competing platform launched a lower-cost sensor bundle this week, which I am watching, but nothing in that launch yet beats Stelo's combination of price and zero-prescription access.

Stelo wins on the math that actually matters: price per day worn

At $49.50 for 15 days, Stelo runs about $3.30 a day with zero prescription friction, and that combination beats every sensor above it on raw accuracy alone. Most people stop wearing a CGM because of cost or hassle, and Stelo removes both.

G7 15 Day is the accuracy benchmark of the category

An 8.0% MARD held across 15.5 days of wear is the tightest accuracy-to-duration ratio I have tested, and that precision is why clinicians still default to Dexcom when therapy decisions are on the line.

Lingo's daily glucose score is what keeps people using it past week two

A single number that updates every day gives Lingo users a reason to open the app after the sensor itself stops feeling new, which solves the engagement drop-off that kills most OTC CGM habits.

Eversense 365's year-long implant is the right answer for the wrong budget

One insertion covering 365 days ends sensor-change fatigue for good, but the $199 to $1,000 annual range and a required clinic visit make it the specialist pick for people who hate changing sensors every two weeks.

References

Update History

2026-10-05

Dexcom's Stelo keeps first place today at 9.3, and the EASD research covered by Citeline Medtech Insight is the reference that best explains why I keep it there over sensors with higher raw accuracy. The studies show CGMs reduce mortality in the populations that use them consistently, but also that awareness and adherence lag the clinical benefit, which makes dailyCost the column that decides whether someone actually keeps wearing a sensor. Stelo's 9.5 dailyCost score, the best on this list, is why it beats the Dexcom G7 15 Day despite the G7's superior 9.8 accuracy score, a sensor nobody can afford to wear consistently helps no one.

MedTech Dive's coverage of Dexcom and Abbott's over-the-counter push adds the market context, both companies are racing to make glucose data available without a prescription, and that race is exactly why Abbott's Lingo holds third at 9.0 with a strong 9.2 app score, the OTC category is being won on software experience as much as sensor chemistry at this point.

For anyone with diagnosed diabetes who needs the highest accuracy regardless of cost, the Dexcom G7 15 Day at second with 9.1 remains my pick, its 9.8 accuracy and 8.5 coaching scores are built for clinical management, the use case it handles best. For everyone else watching metabolic health without a prescription, Stelo's combination of low cost and strong wear time is still the more sustainable choice.

Mortality benefit only matters if people keep wearing the sensor

EASD research cited by Citeline shows CGMs reduce mortality, but adherence lags. Stelo's 9.5 dailyCost score, the best here, is why affordability outranks raw accuracy in my formula.

The OTC race is being won on software now

MedTech Dive's coverage of Dexcom and Abbott's over-the-counter push lines up with Abbott Lingo's 9.2 app score. Sensor chemistry is converging, so the app experience is the new differentiator.

G7 15 Day is still the clinical pick

For diagnosed diabetics who need the highest accuracy regardless of cost, the G7 15 Day's 9.8 accuracy and 8.5 coaching scores outweigh Stelo's affordability advantage.

2026-10-04

Dexcom's Stelo keeps the top spot on its usual strength, a 9.5 daily cost score that remains the lowest barrier to entry of any sensor here. This week's trade coverage of the OTC CGM market confirms Stelo and Lingo are now the two biggest forces pulling glucose monitoring into a mainstream market of 98 million prediabetic adults and millions on GLP-1 drugs, and Dexcom's redesigned Stelo app, now carrying a food database of over a million items with full macro breakdowns, is the reason its 8.5 app score holds up against pricier competitors. Dexcom's G7 15 Day holds second, and its combination of a 9.8 accuracy score, the best in this ranking, with 15 days of wear instead of the standard 10, makes it the sensor I point serious glucose trackers toward when daily cost matters less than data density. Abbott's Lingo holds third on a 9.2 app score, the most polished day to day tracking experience in this list, and the two companies are clearly racing each other on software now that sensor accuracy across the top tier has mostly converged. Eversense 365 still wins wear time outright at a full 10.0, a once a year implant that removes daily sensor changes entirely for anyone who finds adhesive patches irritating. My take remains the same: Stelo's cost advantage and Dexcom's broader hardware lead still make this company the one to beat, but Abbott's app work is closing the gap fast enough that I expect this to stay a genuine two way race through next year.

Stelo's food database now rivals dedicated nutrition apps

Dexcom's redesigned Stelo app logs over a million foods with full macro breakdowns, the specific upgrade behind its 8.5 app score holding up against pricier sensors.

G7 15 Day trades a bit of cost for the longest accurate wear

A 9.8 accuracy score paired with 15 days per sensor instead of the standard 10 makes this the pick for serious trackers who care more about data density than daily price.

Abbott and Dexcom are now racing on software, not sensors

Lingo's 9.2 app score is the most polished tracking experience here, a sign the OTC CGM fight has shifted from raw accuracy, where the top tier has mostly converged, to daily usability.

Eversense 365 removes the daily sensor habit entirely

A once a year implant gives it a perfect 10.0 wear time score, the only real option for anyone who finds adhesive patch sensors irritating after a few days.

2026-10-03

Dexcom's Stelo keeps the top spot on its usual strength, a 9.5 daily cost score that remains the lowest barrier to entry of any sensor here. The bigger story this week comes out of the European Association for the Study of Diabetes meeting in Milan, running September 28 through October 2: a new analysis presented there found that people with Type 2 diabetes on basal insulin who started continuous glucose monitoring had a 44 percent lower risk of dying from any cause within a year, compared with those who didn't start monitoring. Dexcom used the same meeting to publish its State of Type 2 report and announced it's becoming the official CGM of Team Novo Nordisk.

That mortality data is making me adjust how I weigh real-world outcomes against daily cost. FreeStyle Libre 3 Plus moves up to fourth today, swapping places with the G7. Libre 3 Plus wears for 15 days against the G7's roughly 10, and its lower monthly cost works out to real savings over a year of continuous use, the same daily cost math the Milan data just reinforced matters at a population level. I've nudged its daily cost score up to 8.2 to reflect that.

G7 still earns its spot through a 9.6 accuracy score and native Apple Watch support most sensors here can't match. It settles one rank below a 15-day sensor that now has a stronger real-world outcomes case behind it.

Abbott's Lingo holds third on a 9.2 app score built for people managing metabolic health without a diabetes diagnosis, a different job than either Dexcom sensor is built for.

EASD Data Links CGM Use to a 44 Percent Lower Mortality Risk

A new analysis presented in Milan found people with Type 2 diabetes on basal insulin who started CGM had a 44 percent lower one-year risk of dying from any cause compared with those who didn't.

Libre 3 Plus Moves Up on 15-Day Wear and Lower Monthly Cost

Its daily cost score rises to 8.2 today, reflecting the real savings a 15-day sensor delivers over a year of continuous use, the same math behind the Milan mortality data.

G7 Still Leads on Accuracy and Apple Watch Support

A 9.6 accuracy score and native Apple Watch integration keep it a serious pick, one rank below a 15-day sensor with a stronger outcomes case right now.

Dexcom Stelo Remains the Lowest-Barrier Entry Point

A 9.5 daily cost score keeps it the easiest sensor here to try without a prescription or a steep monthly bill.

2026-10-01

Dexcom's Stelo holds the top spot, and its position got more durable this year after the FDA expanded its over-the-counter clearance to include people as young as two who don't use insulin. That's a meaningful regulatory vote of confidence for a device already winning this category on daily cost at 9.5, the lowest barrier to entry of any sensor here.

G7 15 Day earns second place almost entirely on accuracy, a 9.8 MARD score that remains the best clinical performance in this list, plus a wear time that finally matches what patients have asked Dexcom for since the original G6.

Abbott's Lingo climbs to third on its app experience, a 9.2 score built around an interface that explains glucose spikes in plain language alongside the raw numbers. For someone new to metabolic tracking, that clarity is worth more than a marginal accuracy edge.

Eversense 365 remains the wear-time champion at a perfect 10.0, the only sensor here that lasts a full year under the skin, which matters enormously for anyone who finds insertion days to be the worst part of using a CGM.

Nutrisense holds its coaching crown at 9.5, the highest in the category, reflecting a program built around registered dietitians who review data with users directly.

No reordering this cycle. The Stelo news confirms a verdict already in place, and that's exactly how a ranking should respond to good news about an already-strong leader.

Stelo's expanded FDA clearance earns it a stronger hold on first place

The agency's decision to clear Stelo for non-insulin users as young as two widens its addressable market without touching its core 9.5 daily-cost advantage. A device that was already the cheapest path into CGM just became available to more households.

G7 15 Day's accuracy is simply the best in this category

A 9.8 MARD score is the clinical gold standard here, and the extended 15-day wear time finally closes the gap patients complained about with the original G6. This is the sensor I'd point a type 1 diabetic toward first.

Lingo's app makes it the right pick for CGM beginners

A 9.2 app score reflects an interface that translates glucose data into plain-language insight, built for someone who has never read a glucose chart before.

Eversense 365's year-long wear time is a genuine category first

A perfect 10.0 wear-time score reflects an implantable sensor that lasts 365 days, compared to 10-15 days for every other device on this list. For anyone who dreads insertion day, this is the only real answer.

2026-09-30

Dexcom's Stelo holds first place again, and this week's biggest CGM news actually lands on the prescription side of this category, which sharpens a distinction I made last month between wellness tracking and real clinical benefit. Abbott announced results on September 27 from a study of adults with type 2 diabetes on basal insulin, finding that FreeStyle Libre users had a 45 percent lower risk of death at 12 months and a 36 percent lower risk at 24 months compared with people who never used continuous monitoring. IDF Europe's expert opinion this year backs the same pattern, calling CGM integration with insulin therapy one of the clearest wins in diabetes care in 2026. That is a genuinely different claim than the wellness marketing built around devices like Stelo and Lingo, and it is worth knowing which category you actually fall into before you buy. FreeStyle Libre 3 Plus holds its own in my table with a 9.3 accuracy score and a 9.3 wear time score, a real option if you have diabetes and want the clinical grade device behind this new mortality data. Stelo keeps the top spot for the no prescription wellness use case specifically, its 9.5 daily cost score and 9.2 accuracy hold up for people managing prediabetes or watching diet response, a role Dexcom has always been upfront about. Dexcom G7 15 Day leads outright on raw accuracy at 9.8 for readers who need the tightest numbers regardless of price. My advice this month is sharper than usual, if you manage diabetes on insulin, the new mortality data makes a strong case for a prescription CGM like Libre or G7, and if you are healthy and simply curious about your glucose response to food, Stelo remains the smarter, cheaper entry point.

A major mortality finding

Abbott's September 27 announcement found FreeStyle Libre users with type 2 diabetes on basal insulin had a 45 percent lower risk of death at 12 months versus non-users.

IDF Europe backs the trend

IDF Europe's 2026 expert opinion calls CGM integration with insulin therapy one of the clearest wins in diabetes care this year.

FreeStyle Libre 3 Plus for clinical use

A 9.3 accuracy score and 9.3 wear time score make it a real pick for readers managing diabetes with insulin.

Stelo still the wellness pick

A 9.5 daily cost score and 9.2 accuracy keep Stelo on top for no prescription users tracking diet response.

G7 15 Day for raw accuracy

A 9.8 accuracy score leads the whole table for readers who want the tightest numbers regardless of price.

2026-09-29

Dexcom's Stelo holds first place, and this month I want to flag a piece of pushback that anyone buying a no-prescription CGM for general wellness should read. A narrative review from University of Gothenburg researchers, prepared at the request of JAMA Internal Medicine, concluded that CGMs show no proven health benefit for people without diabetes, and warned that normal glucose swings can get misread by healthy users as a problem that needs fixing. That is a fair challenge to the wellness framing a lot of these devices are sold with, and it shifts what I think buyers should expect from the data they see on screen. Stelo stays on top because its accuracy and daily cost numbers hold up regardless of why someone is wearing it, and Dexcom is upfront that Stelo is built for people managing prediabetes or watching diet response, a wellness tracking role well short of a diagnostic tool. For readers with type 2 diabetes specifically, a separate body of research keeps showing a real connection between glucose variability and sleep quality, one study I looked at this month found that obstructive sleep apnea disrupts glucose patterns regardless of diabetes status, which is a good reason to pair a CGM with an honest look at sleep if your numbers do not match your diet. My advice stays consistent, a CGM is a genuinely useful tool if you have diabetes or prediabetes and want to see how food and sleep affect you personally, and its value drops quickly as a general wellness gadget once your glucose is already normal.

A real challenge to the wellness pitch

A JAMA Internal Medicine review by University of Gothenburg researchers found no proven benefit from CGM use in people without diabetes, and warned normal glucose swings can be misread as problems.

Stelo's case still holds up

Stelo keeps its top accuracy and daily cost scores because Dexcom markets it specifically for prediabetes and diet response tracking, a wellness role short of diagnosis.

Sleep and glucose are connected

Research I reviewed this month shows obstructive sleep apnea disrupts glucose variability regardless of diabetes status, worth knowing if your CGM numbers do not match your diet.

Who actually benefits

The clearest case for a CGM remains diabetes or prediabetes management, where seeing your personal food and sleep response in real time changes daily decisions.

2026-09-28

Dexcom's Stelo stays first, and this week I want to flag a real shift in the guidelines that back up why a no-prescription CGM like this one now makes sense for more people. The American Diabetes Association updated its 2026 Standards of Care, and Recommendation 9.25 now tells clinicians to recommend continuous glucose monitoring for adults with type 2 diabetes on any treatment where CGM aids management, not only for people using insulin. That change carries grade B evidence, a real upgrade from older guidance that reserved the strong recommendation mostly for insulin users. For a reader shopping this list, it matters because Stelo, Abbott's Lingo, and the FreeStyle Libre 3 Plus are all built for exactly the population this update newly covers, people managing type 2 diabetes with metformin or another non-insulin therapy who want to see how food and exercise move their glucose in real time. Stelo keeps my top spot because its daily cost score of 9.5 is the best on this list, and a lower price per day matters more now that more people have a clinical reason to try one. The Dexcom G7 15 Day earns second place because it pairs a 9.8 accuracy score with a 9.3 wear time score, the strongest combination among the prescription sensors here. Abbott's Lingo holds third with a 9.2 app score, second only to Levels among every sensor on this list, and that keeps daily glucose data easy to read for someone who isn't a clinician. If a doctor has been on the fence about writing a CGM order for a non-insulin type 2 diagnosis, this update gives them a citation to point to, and it is why I expect the no-prescription tier of this list to keep growing.

ADA widens who should get a CGM

The 2026 Standards of Care update Recommendation 9.25 to recommend CGM for adults with type 2 diabetes on any treatment where it aids management, graded B evidence, not only for insulin users.

Stelo wins on daily cost

Stelo posts a 9.5 daily cost score, the best on this list, which matters more now that non-insulin type 2 patients have a clearer clinical reason to start wearing one.

G7 15 Day pairs accuracy and wear time

The G7 15 Day scores 9.8 on accuracy and 9.3 on wear time, the strongest combination among the prescription sensors here.

Lingo keeps data readable

Lingo's 9.2 app score is second only to Levels on this entire list, and that keeps daily glucose trends easy to read for someone without a medical background.

2026-09-27

Stelo stays first, and today I want to look at where the sensor market is heading, because it shapes how I would buy now. Search coverage this month reports that Abbott received CE Mark approval for Libre Duo and Libre Duo 10 Day, sensors that track glucose and ketones from one wearable. Dexcom has also redesigned the Stelo app with more AI features and announced expansion plans that include the United Kingdom, Australia, New Zealand and South Korea. Dexcom has shown early details of the G8 too, with a launch expected in late 2027 or early 2028. None of this changes my table today, since Libre Duo is a European approval and the G8 is more than a year away. What it tells me is that the category keeps improving, so I favor products I can start now without a long commitment. Stelo leads because it is available without a prescription, has a friendly app and gives a clear picture of how meals affect you. Dexcom G7 15 Day is second for longer wear, and Abbott Lingo is third for its simple over the counter access. Wear one for two weeks, log what you eat, and look for patterns across days. That habit teaches more than any individual number. Talk to your clinician if you manage diabetes.

Libre Duo tracks glucose and ketones

Abbott received CE Mark approval for Libre Duo and Libre Duo 10 Day, a European approval for now.

Stelo app gets AI features

Dexcom redesigned the app and announced expansion into more countries.

G8 is a long way off

Expected launch is late 2027 or early 2028, so I rank what you can buy today.

Log meals for two weeks

Patterns across days teach more than any single reading.

2026-09-26

Stelo stays on top, and today I want to explain why over the counter access shapes my ordering. MedTech Dive's explainer on the first over the counter CGMs covers Dexcom's Stelo and Abbott's Lingo, and it is a good primer for anyone who wants glucose data without a prescription. Abbott also sells Libre Rio for adults with type 2 diabetes who do not use insulin.

Stelo leads because buying it is simple and the app experience keeps improving. Dexcom has redesigned the Stelo app with more AI features and has announced expansion to the United Kingdom, Australia, New Zealand and South Korea in 2026, which tells me the company is committed to the consumer side. G7 15 Day at second is my choice for people who prefer a longer wear window on a prescription sensor.

Lingo at third is a strong option for metabolic health curiosity, and FreeStyle Libre 3 Plus remains one of the smallest sensors on the market, roughly the size of two stacked pennies. Eversense 365 keeps a place for people who want an implanted sensor and fewer changes per year. Senseonics also partnered with Welldoc in June to build a new Eversense 365 mobile app that connects with Apple Health and Google Health Connect.

Type1Strong's 2026 roundup is worth reading for hands on impressions of accuracy. Nothing this week shifts my scores, so the order stays. If you are new to CGMs, start with an over the counter sensor for two weeks and learn from your own meals.

Over the counter is here

Stelo and Lingo can be bought without a prescription, and Libre Rio serves non-insulin type 2 adults.

Stelo app redesign

Dexcom added AI features and plans expansion to the UK, Australia, New Zealand and South Korea in 2026.

Eversense app update

Senseonics and Welldoc are building a new app with Apple Health and Google Health Connect support.

Compact Libre 3 Plus

Roughly the size of two stacked pennies, with readings sent every minute.

2026-09-25

Stelo stays on top, and the newest news in this category comes from Abbott, which is worth a careful read. On August 25 the FDA authorized Libre Duo 10 Day, a sensor that reads glucose and ketones together every minute across a ten-day wear, for people with diabetes ages 2 and older. Abbott says it will launch in the U.S. later this year and has shared neither a date nor a price, so I am scoring nothing on it today.

What I take from it is direction. Ketone sensing addresses diabetic ketoacidosis, a real emergency for insulin users, and Abbott expects compatibility with the Beta Bionics iLet and Sequel twiist systems by the end of 2026, with Insulet and Tandem planned for 2027. A sensor that plugs into more pumps is a stronger long-term bet, which supports the case for the Abbott products already on this list.

For most readers of this ranking the buying logic stays simple. Stelo scores 9.5 on daily cost and 9.3 on wear time, and it needs no prescription, which makes it the easiest way to learn how your body responds to meals. The G7 15 Day carries a 9.8 accuracy score, the best here, and it earns second place for anyone dosing insulin. Lingo keeps its 9.2 app score, the friendliest interface for a first-time wearer.

My advice is to wait for Libre Duo pricing before making any decision that depends on it, and to buy the sensor that fits your goal today.

Libre Duo authorized

The FDA authorized Abbott's Libre Duo 10 Day on August 25, tracking glucose and ketones every minute for ten days.

No price yet

Abbott plans a U.S. launch later in 2026 and has not published a date or price, so scores stay unchanged.

Pump compatibility

Abbott expects iLet and twiist compatibility by the end of 2026, with Insulet and Tandem in 2027.

Stelo still leads

Stelo pairs a 9.5 daily cost score with 9.3 wear time and needs no prescription.